Literature DB >> 8275387

Role of cytokines in the regulation of bone resorption.

G D Roodman1.   

Abstract

The process of bone remodeling involves complex interactions between the osteoclast, the primary bone-resorbing cell, and other cells in its microenvironment. These interactions can regulate bone resorption through two processes: (1) effects on the number of osteoclasts present at a given site and (2) effects on the bone-resorbing capacity of individual osteoclasts. Cells present in the osteoclast microenvironment include marrow stromal cells, osteoblasts, macrophages, T-lymphocytes, and marrow cells. These cells, as well as the osteoclast itself, produce cytokines that can affect osteoclast formation and osteoclast activity. In vitro model systems using rodent organ cultures or long-term marrow culture systems, and in vivo models have demonstrated that cytokines such as interleukin-1, M-CSF, tumor necrosis factor, and interleukin-6 can stimulate the formation and bone-resorbing capacity of osteoclasts. In contrast, cytokines such as interleukin-4, gamma-interferon, and transforming factor-beta inhibit both osteoclast formation and osteoclast activity. The relative proportions of these cytokines in the marrow microenvironment may play a critical role in regulating osteoclast activity. Knowledge of cytokines that affect osteoclast formation and activity and their capacity to modulate the bone-resorbing process should provide critical insights into normal calcium homeostasis and disorders of bone turnover such as osteoporosis and Paget's disease of bone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8275387     DOI: 10.1007/bf01673412

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  39 in total

1.  Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells.

Authors:  D G Walker
Journal:  Science       Date:  1975-11-21       Impact factor: 47.728

2.  Expression of human transforming growth factor alpha by Chinese hamster ovarian tumors in nude mice causes hypercalcemia and increased osteoclastic bone resorption.

Authors:  A J Yates; B F Boyce; G Favarato; T B Aufdemorte; C Marcelli; M B Kester; R Walker; B C Langton; L F Bonewald; G R Mundy
Journal:  J Bone Miner Res       Date:  1992-07       Impact factor: 6.741

3.  Interleukin 4 inhibits murine osteoclast formation in vitro.

Authors:  A Shioi; S L Teitelbaum; F P Ross; H G Welgus; H Suzuki; J Ohara; D L Lacey
Journal:  J Cell Biochem       Date:  1991-11       Impact factor: 4.429

4.  Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro.

Authors:  J Pfeilschifter; C Chenu; A Bird; G R Mundy; G D Roodman
Journal:  J Bone Miner Res       Date:  1989-02       Impact factor: 6.741

5.  Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and epo to stimulate human progenitor cells of the myeloid and erythroid lineages.

Authors:  I K McNiece; K E Langley; K M Zsebo
Journal:  Exp Hematol       Date:  1991-03       Impact factor: 3.084

6.  Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis.

Authors:  C W Löwik; G van der Pluijm; H Bloys; K Hoekman; O L Bijvoet; L A Aarden; S E Papapoulos
Journal:  Biochem Biophys Res Commun       Date:  1989-08-15       Impact factor: 3.575

7.  Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria.

Authors:  A H Tashjian; E F Voelkel; M Lazzaro; F R Singer; A B Roberts; R Derynck; M E Winkler; L Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

8.  Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone.

Authors:  Y Ohsaki; S Takahashi; T Scarcez; A Demulder; T Nishihara; R Williams; G D Roodman
Journal:  Endocrinology       Date:  1992-11       Impact factor: 4.736

9.  Recombinant human transforming growth factor-alpha stimulates the formation of osteoclast-like cells in long-term human marrow cultures.

Authors:  N Takahashi; B R MacDonald; J Hon; M E Winkler; R Derynck; G R Mundy; G D Roodman
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

10.  Identification of osteoclast-specific monoclonal antibodies.

Authors:  M J Oursler; L V Bell; B Clevinger; P Osdoby
Journal:  J Cell Biol       Date:  1985-05       Impact factor: 10.539

View more
  27 in total

1.  Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease.

Authors:  C Schulte; H Goebell; H D Röher; K M Schulte
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

2.  Bone mass and mineral metabolism in HIV+ postmenopausal women.

Authors:  Michael Yin; Jay Dobkin; Karen Brudney; Carolyn Becker; Janis L Zadel; Monica Manandhar; Vicki Addesso; Elizabeth Shane
Journal:  Osteoporos Int       Date:  2005-03-08       Impact factor: 4.507

Review 3.  Bone changes and fracture risk in individuals infected with HIV.

Authors:  Amy H Warriner; Michael J Mugavero
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

4.  Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

Authors:  Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Pablo Tebas; Laurie Myers; Kathleen Melbourne; Belinda Ha; Paul E Sax
Journal:  J Infect Dis       Date:  2011-06-15       Impact factor: 5.226

5.  Novel effects of sarcopenic osteoarthritis on metabolic syndrome, insulin resistance, osteoporosis, and bone fracture: the national survey.

Authors:  S M Chung; M H Hyun; E Lee; H S Seo
Journal:  Osteoporos Int       Date:  2016-05-13       Impact factor: 4.507

6.  Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.

Authors:  Ehud Segal; Huaizhong Pan; Liat Benayoun; Pavla Kopečková; Yuval Shaked; Jindřich Kopeček; Ronit Satchi-Fainaro
Journal:  Biomaterials       Date:  2011-03-22       Impact factor: 12.479

7.  The association between bone mineral density and metabolic syndrome: a Korean population-based study.

Authors:  Hoon Kim; Han Jin Oh; Hoon Choi; Woong Hwan Choi; Sung-Kil Lim; Jung Gu Kim
Journal:  J Bone Miner Metab       Date:  2013-03-26       Impact factor: 2.626

8.  Association of lipid parameters and insulin resistance with bone health in South Korean adolescents.

Authors:  S-W Park; G-E Nam; D-W Jung; S-J Yoon; K Han; Y-G Park; J-S Choi; J-E Lee; J-E Sang; Y-J Yoon; D-H Kim
Journal:  Osteoporos Int       Date:  2015-09-02       Impact factor: 4.507

Review 9.  The Relationship Between Polycystic Ovarian Syndrome, Periodontal Disease, and Osteoporosis.

Authors:  Hannah E Young; Wendy E Ward
Journal:  Reprod Sci       Date:  2020-09-10       Impact factor: 3.060

10.  Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids.

Authors:  George S Habib; Shehadeh Haj
Journal:  Clin Rheumatol       Date:  2004-09-14       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.